Search

Your search keyword '"Rusman, Tamara"' showing total 2 results
Start Over Author "Rusman, Tamara" Topic ankylosing
2 results on '"Rusman, Tamara"'

1. Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis

Author

Stovall, Rachael, van der Horst-Bruinsma, Irene E, Liu, Shao-Hsien, Rusman, Tamara, and Gensler, Lianne S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Arthritis, Autoimmune Disease, 2.1 Biological and endogenous factors, Aetiology, Musculoskeletal, Male, Female, Humans, Spondylarthritis, Prevalence, Sex Characteristics, Axial Spondyloarthritis, Spondylitis, Ankylosing, Clinical sciences
Abstract

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that predominantly affects the axial skeleton, although it can affect peripheral joints, and extra-musculoskeletal manifestations also occur. Historically, axSpA was thought to be a disease predominantly seen in men, although with the advent of magnetic resonance imaging techniques and advances in research, this dogma has been challenged and refuted. Sex and gender are different concepts, and both can have a role in disease. In axSpA, consideration of the influence of sex and gender on the disease phenotype is necessary to predict outcomes and to enable the development of therapeutic approaches that are best suited to individual patients.

Published
2022

2. Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice.

Author

Rusman, Tamara, ten Wolde, Saskia, Euser, Sjoerd M., van der Ploeg, Tjeerd, van Hall, Odile, and van der Horst‐Bruinsma, Irene E.

Subjects
*ANKYLOSING spondylitis treatment, *RHEUMATOID arthritis, *TUMOR necrosis factors, *HEALTH outcome assessment, *PALLIATIVE treatment
Abstract

Abstract: Aim: To assess gender differences in ankylosing spondylitis (AS) patients in relation to tumor necrosis factor alpha inhibitor (TNFi) drug survival and occurrence of adverse events in daily practice in a large peripheral hospital. Method: Retrospective data were collected from AS patients treated with etanercept, infliximab and adalimumab between January 2004 and January 2014. Kaplan–Meier survival curves were conducted to describe the drug survival and occurrence of adverse events in time. Results: Overall, 122 AS patients (60.7% male) were included over a 10‐year time period, with a mean treatment period of 51 months (1–127 months). In total, 21 (17.2%) patients stopped the TNFi, mainly due to inefficacy (52.4%). Female patients showed a significant shorter treatment period compared to males (33.4 vs. 44.9 months). In addition, female patients switched more between TNFi compared to males (26.9% vs. 16.3%) and had a significantly higher risk at developing infections compared to male patients (26% vs.19%). Conclusion: Females stayed on the same TNFi for a significantly shorter period compared to males (33.4 vs. 44.9 months) and the most important reason to stop or switch the drug was inefficacy. Moreover, females seemed to be more prone to infections during TNFi treatment than males. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results